Cancer Treatment in China: Hospitals, Methods & Costs

Cancer Treatment Methods Available in China

China’s leading cancer centres offer standard surgery, chemotherapy and radiotherapy, plus several advanced methods that patients often travel for. Which one fits depends on the type of cancer, its stage and your test results. Here is a quick guide, with a detailed page for each method.

• CAR-T cell therapy: mainly used for some blood cancers, such as lymphoma, leukaemia and myeloma, usually after other treatments have stopped working.
• Proton therapy: a precise form of radiotherapy that can spare healthy tissue. It is often considered for tumours near sensitive organs and for children.
• Cryoablation: destroys tumours by freezing them through a thin needle. It may suit patients who cannot have surgery.
• NanoKnife (IRE): uses electrical pulses instead of heat or cold. It is sometimes used for tumours close to major blood vessels, such as in the pancreas.
• Interventional oncology: minimally invasive treatments, including microwave ablation, guided by imaging.

Wondering what it will cost? See our cancer treatment cost guide and compare leading cancer hospitals in China.

The fastest way to know which method makes sense for you is a doctor’s review of your file. Send us your diagnosis, pathology report and recent scans. We will tell you which options are realistic, which hospital offers them and what the next steps are. The review is free.

What actually changes the plan

What this page helps you decide

Who this page is for

What you can actually book

Histology, stage, prior lines and the relevant panel (EGFR, ALK, PD-L1, HER2, CLDN18.2, BRCA, and others as relevant), then a shortlist of public MDTs. Organ pages: lung, breast, liver, stomach / satri-cel, prostate, CAR-T, proton, Fuda, cost.

What moves the cost

These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.

What happens next

Sources

IARC/WHO GLOBOCAN 2024 China fact sheet.
NCCN clinical practice guidelines; NCCN public note on use in China.
NMPA satri-cel approval 22 June 2026; Lancet phase 2 PFS/toxicity figures.
SPHIC / municipal reporting of the RMB 278,000 particle-course fee.
Public descriptions of CAMS/NCC, PKU Cancer, FUSCC, SYSUCC, Ruijin.

Freshness label on this page: 2026-08-15

Medical note

A treating oncologist in your home country should review imaging and pathology before you travel. This page is matching information, not a treatment recommendation.

Chemotherapy is a class, not a package

Chemotherapy is one treatment class. Choosing it requires a diagnosis, the stage, the histology, the biomarkers, previous treatment, performance and organ status, and a regimen. The same facts decide whether targeted therapy, immunotherapy, radiotherapy, or a local procedure belongs beside it.

CAR-T, stem-cell transplantation, and experimental cell therapy for solid tumors are not chemotherapy and are not sold here as one advanced-cancer bundle. Labeled solid-tumor CAR-T on this page remains the narrow satri-cel indication. Other solid-tumor cell programs need a trial identifier. CAR-T therapy in China is the cell-therapy page. Proton therapy and interventional oncology stay separate. There is no fixed national price per cycle. The cost page says the bill depends on the drugs, the dose, and the number of cycles.

What medical records are needed for cancer treatment in China?

These are the documents a department usually asks to see. Slides and blocks are included only when that department requests them. A PET-CT report is included when the patient already has one. Ordering PET-CT for every cancer is not the rule.

• Pathology report
• Pathology slides or blocks, where the department asks for them
• CT, MRI, and PET-CT reports that already exist
• Imaging files
• Operation reports
• Discharge summaries
• Chemotherapy history
• Radiotherapy history
• Targeted-therapy and immunotherapy history
• Molecular and biomarker testing
• Recent blood tests
• Current medications

Do not type the diagnosis, stage, pathology, biomarkers, or record text into an analytics field. This list does not replace the intake already on this page, and it does not create a second form. Access compared with care at home, without a country ranking, is on cancer treatment in China vs the US.

From the file to follow-up

1. Send the case summary and the records the department asks for.
2. Records are screened. Screening is not a promise of treatment.
3. A department is matched to the diagnosis, not to a slogan.
4. International-patient access is confirmed for that department.
5. The department reviews the file.
6. A preliminary plan is labeled as ordinary care, a named product, or a trial.
7. A written estimate is requested. The estimate is not the final bill.
8. An appointment is confirmed only after the department agrees.
9. Support documents are requested only if that hospital issues them. Issuing a document is not visa approval.
10. Travel and admission follow the current passport rules.
11. Treatment follows the accepted plan.
12. Discharge papers go home with the patient. The home physician continues follow-up. The China team does not automatically transfer.

Acceptance by a provider is not approval of a visa. Reviewing a file is not the same as accepting treatment. A written estimate is not the final bill. A trial on a list is not eligibility for that trial.

Stay length is not universal. Calendars already published for a short review, surgery, radiation, and CAR-T sit on the medical visa page.

Next useful pages